Related Experiment Video
Updated: Feb 16, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Therapeutic Cancer Vaccines: How Much Closer Are We?
17007 Wisconsin Institutes for Medical Research, University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, Madison, WI, 53705, USA. dm3@medicine.wisc.edu.
Abstract:
The promise of immune-based therapies to treat cancer has been realized over the last several years with several breakthrough therapies, including T-cell checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapies. While cancer vaccines have been investigated for many decades, to date only one has been approved in the USA as a treatment for existing cancer. The failure of several anti-tumor vaccines in large phase III trials has led many to question their future role in cancer treatment. Trials to date have demonstrated that many cancer vaccines can elicit tumor-specific T cells, but these T cells may be insufficient to mediate substantial anti-tumor effects without concurrent blockade of tumor-resistance mechanisms. Emerging data from preclinical models and clinical trials demonstrate that cancer vaccines have greater activity in low-volume disease and in combination with other immune-modulating therapies, including T-cell checkpoint blockade, targeting these resistance mechanisms. Because T-cell checkpoint therapies likely require the presence or activity of tumor-specific T cells, cancer vaccines may be optimal agents to use in combination to enable these therapies to work for greater numbers of patients. Future trials will explore optimal vaccine approaches and antigens that work best in combination treatment approaches and in earlier stages of disease.
Insights
Cancer vaccines show promise when combined with immune-modulating therapies like T-cell checkpoint inhibitors, especially for early-stage or low-volume disease. This combination approach may enhance treatment efficacy for more patients.
Area of Science:
- Immunotherapy
- Oncology
- Vaccinology
Background:
- Immune-based cancer therapies, including T-cell checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapies, have shown significant success.
- Despite decades of research, only one cancer vaccine is approved in the USA for treating existing cancer, with several failing in late-stage trials.
- Existing cancer vaccines can generate tumor-specific T cells, but these are often insufficient to eliminate tumors without addressing resistance mechanisms.
Purpose of the Study:
- To evaluate the potential of cancer vaccines in combination with other immunotherapies.
- To explore the role of cancer vaccines in treating low-volume disease and in conjunction with T-cell checkpoint blockade.
- To determine if cancer vaccines can enhance the efficacy of T-cell checkpoint therapies for a broader patient population.
Main Methods:
- Review of emerging data from preclinical models.
- Analysis of clinical trial outcomes for cancer vaccines.
- Investigation of combination strategies involving cancer vaccines and immune-modulating therapies, including T-cell checkpoint blockade.
Main Results:
- Cancer vaccines demonstrate enhanced activity in preclinical models and clinical trials when used for low-volume disease.
- Combination therapy, particularly with T-cell checkpoint blockade, shows increased anti-tumor effects by targeting resistance mechanisms.
- Cancer vaccines may prime the immune system, providing the necessary tumor-specific T cells for T-cell checkpoint therapies to be effective.
Conclusions:
- Cancer vaccines are most effective when combined with other immune-modulating therapies that address tumor resistance.
- Combining cancer vaccines with T-cell checkpoint inhibitors holds significant potential for improving treatment outcomes in a larger number of cancer patients.
- Future research should focus on optimizing vaccine strategies, identifying optimal antigens, and testing these combinations in earlier stages of cancer.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations
01:13Therapeutic Index
01:30Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:29Microorganisms in Medicine and Therapeutics